List of Contents

Prenatal and Newborn Genetic Testing Market Size, Share, and Trends 2024 to 2033

Prenatal and Newborn Genetic Testing Market (By Technology: Screening Method, Diagnostic Technology; By Diseases: Down Syndrome, Phenylketonuria, Cystic fibrosis, Sickel Cell Anemia; By End-use: Hospitals, Maternity and Specialty Clinics, Diagnostic Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : July 2024
  • Report Code : 4630
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Prenatal and Newborn Genetic Testing Market 

5.1. COVID-19 Landscape: Prenatal and Newborn Genetic Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Prenatal and Newborn Genetic Testing Market, By Technology

8.1. Prenatal and Newborn Genetic Testing Market, by Technology, 2024-2033

8.1.1 Screening Method

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Diagnostic Technology

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Prenatal and Newborn Genetic Testing Market, By Diseases

9.1. Prenatal and Newborn Genetic Testing Market, by Diseases, 2024-2033

9.1.1. Down Syndrome

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Phenylketonuria

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Cystic fibrosis

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Sickel Cell Anemia

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Prenatal and Newborn Genetic Testing Market, By End-use 

10.1. Prenatal and Newborn Genetic Testing Market, by End-use, 2024-2033

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Maternity and Specialty Clinics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Diagnostic Centers

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Prenatal and Newborn Genetic Testing Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Technology (2021-2033)

11.1.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.1.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.1.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.1.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.1.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.1.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Technology (2021-2033)

11.2.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.2.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.2.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.2.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.2.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.2.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Technology (2021-2033)

11.2.6.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.2.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Technology (2021-2033)

11.2.7.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.2.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Technology (2021-2033)

11.3.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.3.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.3.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.3.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.3.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.3.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Technology (2021-2033)

11.3.6.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.3.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Technology (2021-2033)

11.3.7.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.3.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.4.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.4.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.4.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.4.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Technology (2021-2033)

11.4.6.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.4.6.3. Market Revenue and Forecast, by End-use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Technology (2021-2033)

11.4.7.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.4.7.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.5.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Technology (2021-2033)

11.5.4.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.5.4.3. Market Revenue and Forecast, by End-use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Technology (2021-2033)

11.5.5.2. Market Revenue and Forecast, by Diseases (2021-2033)

11.5.5.3. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 12. Company Profiles

12.1. Agilent Technologies, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Ariosa Diagnostics, Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Bio-Rad Laboratories, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Laboratory Corporation of America Holdings (LabCorp)

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Natera, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. PerkinElmer, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Sequenom, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client